|1.||Hedlund, G: 7 articles (11/2003 - 10/2000)|
|2.||Hedlund, Gunnar: 3 articles (12/2004 - 02/2002)|
|3.||Thorlacius, H: 3 articles (11/2003 - 11/2000)|
|4.||Xiao, Zhi-Yong: 2 articles (12/2007 - 10/2007)|
|5.||Zhang, Yong-Xiang: 2 articles (12/2007 - 10/2007)|
|6.||Yun, Liu-Hong: 2 articles (12/2007 - 10/2007)|
|7.||He, Jun-Feng: 2 articles (12/2007 - 10/2007)|
|8.||Zhou, Wen-Xia: 2 articles (12/2007 - 10/2007)|
|9.||Yang, Ri-Fang: 2 articles (12/2007 - 10/2007)|
|10.||Cheng, Jun-Ping: 2 articles (12/2007 - 10/2007)|
11/01/1999 - "In vivo nuclear magnetic resonance analysis of tumor blood flow in linomide-treated animals showed localization of blood vessels almost exclusively to the periphery of the poorly vascularized tumors with a significant reduction of both vascular functionality and vasodilation. "
11/01/1999 - "The aim of this study was to ascertain the potential usefulness of the antiangiogenic compound linomide for treatment of von Hippel-Lindau (VHL)-related tumors. "
05/01/1995 - "These studies also demonstrated that linomide does not decrease the attachment, migration, or invasive abilities of metastatic cancer cells. "
05/01/1995 - "To test if this antimetastatic response is due to direct effects of linomide on the metastatic cells themselves as well as an induced effect upon inhibition of tumor angiogenesis, additional studies were performed. "
12/01/2002 - "Although linomide regulates anti-self reactivity in mice with experimental and spontaneous autoimmune disorders, the anti-tumor effects induced by allogeneic donor lymphocytes were not affected. "
|2.||Autoimmune Diseases (Autoimmune Disease)
01/01/1997 - "Linomide (quinoline-3-carboxamide), a well tolerated, orally administered compound was recently shown to be effective in the prevention and treatment of several autoimmune diseases in experimental animal models. "
12/01/1986 - "The results obtained suggest that LS-2616 may be useful in the treatment of autoimmune disease in man."
12/01/1993 - "Linomide, a new treatment for autoimmune diseases: the potential in type 1 diabetes."
12/15/2007 - "Linomide is an immunomodulator that can effectively inhibit the development of several autoimmune diseases in animal models. "
10/27/2007 - "Roquinimex is an immunomodulator that can effectively inhibit the development of several autoimmune diseases in animal models, but the mechanism is still unknown. "
|3.||Body Weight (Weight, Body)
06/01/2000 - "In this study 278 AML patients in remission were randomized to receive Roquinimex 0.2 mg/kg body weight or placebo twice weekly for 2 years following ABMT. "
10/01/1999 - "As part of a phase III placebo-controlled multicenter study patients were randomized to receive Roquinimex, 0.2 mg/kg body weight, or a placebo twice weekly for a duration of 2 yr following autologous bone marrow transplantation for acute myeloid leukemia in remission. "
11/01/1996 - "injection of 1 g/kg body weight glucose: Linomide plus isograft 6.7 +/- 1 mmol/L; Linomide alone 18.7 +/- 6.3 mmol/L; p < 0.0001]. "
|4.||Prostatic Neoplasms (Prostate Cancer)
08/15/1995 - "These studies demonstrated that linomide treatment decreases microvessel density in both androgen-independent human prostatic cancers. "
05/01/1995 - "These studies demonstrated that linomide is not converted in vivo to metabolite(s) which are directly cytotoxic or cytostatic to the prostatic cancer cells themselves. "
06/01/1992 - "These studies demonstrated that linomide has a reproducible antitumor effect against all of the prostatic cancers tested regardless of their growth rate, degree of morphologic differentiation, metastatic ability, or androgen responsiveness. "
03/15/1997 - "Based on their different but complementary mechanisms of action, simultaneous combination of androgen ablation with Linomide enhances the anti-prostatic cancer efficacy compared to either monotherapies alone and warrants testing in humans."
08/15/1995 - "Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide."
10/01/1998 - "The synthetic immunomodulatory substance linomide has been successfully used to prevent the development of several experimental autoimmune models in laboratory animals and has been proved to be beneficial in modulating the course of multiple sclerosis in humans. "
06/01/2001 - "Linomide has been evaluated in clinical trials for multiple sclerosis, and was indeed shown to have disease inhibitory effects. "
04/01/2000 - "Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials."
11/01/1997 - "Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4+/CD45RA+ cells and downregulation of CD4+/CD45RO+ cells."
08/01/1996 - "[Immune modulation in multiple sclerosis: linomide]."
|3.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|4.||Interleukin-10 (Interleukin 10)
|5.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||Interleukin-4 (Interleukin 4)
|9.||Transforming Growth Factor beta2
|1.||Bone Marrow Transplantation (Transplantation, Bone Marrow)